Hi ajostu - I perhaps wouldn’t quite express it quite a negatively as you are. There is always an element of used car salesman in all microcap biotech. This is situation normal.
The point of the post was to suggest this second trial might be a bit less definitive or binary than everyone thinks. It is P2b … safety is the primary and it is typical for secondaries to have low power.
Why is everyone on board? “If you build it they will come” in under-funded disease spaces.
I’m not sure I understand your second question. There are a 101 ways companies deal with lack of statistical significance on P2 efficacy outcomes where those null results have most likely occurred through lack of power. You could write a book on this.
But we are putting the cart before the horse.
One perhaps subtle distinction ajostu. Drugs couldn’t care less what the sample size of a trial is. Or what happens to companies with good or bad trial results. Drugs work (or not) in their own reality. So power (formally) has nothing to do with whether an effect is there or not. Its just the probability of detecting it if in fact it is actually there in the first place.
All the best Southoz
NEU Price at posting:
5.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)